Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2012; 18(6): 498-506
Published online Feb 14, 2012. doi: 10.3748/wjg.v18.i6.498
Published online Feb 14, 2012. doi: 10.3748/wjg.v18.i6.498
Table 2 Agents with antiangiogenic properties in development for the treatment of hepatocellular carcinoma
Agent | Therapeutic target | Phase of study |
Brivanib | VEGFR, FGFR | III |
Bevacizumab | VEGF | II |
Ramucirumab | VEGFR-2 | III |
ABT-869 | VEGFR-1, VEGFR-2, PDGFR-β, c-KIT, Flt-3 | III |
Everolimus | mTOR | III |
ARQ 197 | c-MET | II |
- Citation: Frenette C, Gish R. Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications. World J Gastroenterol 2012; 18(6): 498-506
- URL: https://www.wjgnet.com/1007-9327/full/v18/i6/498.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i6.498